MedStar Authors catalog › Details for: Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. [Review]
Normal view MARC view ISBD view

Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. [Review]

by Barnhill, Michele; Steinberg, Joshua M.
Citation: Current Gastroenterology Reports. 22(9):47, 2020 Jul 15..Journal: Current gastroenterology reports.Published: ; 2020ISSN: 1522-8037.Full author list: Barnhill MS; Steinberg JM; Jennings JJ; Lewis JH.UI/PMID: 32671616.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Washington Hospital CenterDepartment(s): Medicine/Internal Medicine | Medicine/GastroenterologyActivity type: Journal Article.Medline article type(s): Journal Article | ReviewDigital Object Identifier: https://dx.doi.org/10.1007/s11894-020-00781-3 (Click here) Abbreviated citation: Curr Gastroenterol Rep. 22(9):47, 2020 Jul 15.Abstract: PURPOSE OF REVIEW: As treatment options for inflammatory bowel disease (IBD) continue to expand, the opportunity for hepatotoxicity remains a clinical concern. This review looks to update the current literature on drug-induced liver injury (DILI) and liver-related complications from current and emerging treatments for Crohn's disease (CD) and ulcerative colitis (UC).Abstract: RECENT FINDINGS: An extensive literature review on currently used medications to treat IBD and their liver-related side effects that includes mesalamine, thiopurines, certain antibiotics, methotrexate, anti-TNF agents including recently introduced biosimilars, anti-integrin therapy, anti-IL 12/IL 23 therapy, and small molecule JAK inhibitors. Hepatotoxicity remains an important clinical issue when managing patients with IBD. Clinicians need to remain aware of the potential for liver-related adverse events with various medication classes and adjust their clinical monitoring as appropriate based on the agents being used.

Powered by Koha